Friday 6 November 2026 Export ZLAB’s income statement to Excel — free account

Zai Lab Limited Unsponsored ADR

Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.

Revenue: −6.79%
EPS: −24.3%
Free cash flow: −95.5%
Total debt: +24.3%

Quarter to September 2026, against a year earlier

25.72 3.12 +13.81%

Follow ZLAB

Alert me

Market cap: $2.6B
P/E: 0.0×
Fwd P/E: −10.0×
Dividend yield: —
F-score: 4/9
Altman Z: −0.24
Beneish M: −2.35
Dividend safety: n/a

Overview

Zai Lab Limited Unsponsored ADR (ZLAB) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Zai Lab Limited Unsponsored ADR (ZLAB) trades at a P/B ratio of 4.5×. Over the past ten years it has ranged from 0.0× (September 2019) to 21.8× (December 2020); the current reading is higher than 70% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ZLAB/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Zai Lab Limited Unsponsored ADR P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ZLAB/metrics/pb-ratio">Zai Lab Limited Unsponsored ADR (ZLAB) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	2.7×	(12.38%)
FY2024	3.1×	(2.58%)
FY2023	3.2×	11.95%
FY2022	2.8×	(33.28%)
FY2021	4.2×	(52.89%)
FY2020	9.0×	(31.11%)
FY2019	13.0×	—
FY2018	0.0×	—

Period	P/B ratio	Change
Sep 2026	5.2×	49.40%
Jun 2026	3.5×	11.11%
Mar 2026	3.1×	16.52%
Dec 2025	2.7×	(45.05%)
27 more quarters	Free account

Against its own ten years

Low 0.0× High 21.8×

Ten-year median 3.2×

Current reading's percentile 62

Company	P/B ratio
RXRX Recursion Pharmaceuticals, Inc. compare	2.1×
CLDX Celldex Therapeutics, Inc. compare	3.1×
NAMS NewAmsterdam Pharma Company N.V. compare	3.7×
ZLAB Zai Lab Limited Unsponsored ADR	4.5×
XNCR Xencor, Inc. compare	5.2×
MBX MBX Biosciences, Inc. compare	5.7×
RCUS Arcus Biosciences, Inc. compare	6.4×
PHVS Pharvaris N.V. compare	6.4×
ADMA ADMA Biologics Inc compare	6.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Zai Lab Limited Unsponsored ADR (ZLAB) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ZLAB

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ZLAB

Stockrow Weekly